European Society of Cardiology

High salt intake was associated with a twofold increase in the risk for heart failure, according to findings recently presented at the European Society of Cardiology Congress in Barcelona.

Administering IV fentanyl during PCI delayed the absorption of ticagrelor by as many as 4 hours, according to a poster presented at the European Society of Cardiology Congress.

Patients who underwent left atrial appendage closure during open heart surgery had reduced the risk for long-term ischemic brain damage, according to the LAACS study presented at the European Society of Cardiology Congress.

Incidence of major coronary events was significantly reduced among patients with atherosclerotic vascular disease who received statin therapy with the addition of the cholesterol ester transfer protein inhibitor anacetrapib, according to data presented at the European Society of Cardiology Congress.

Patients with osteoarthritis or rheumatoid arthritis and elevated risk for CVD who were treated with ibuprofen had increased systolic BP in addition to the risk for hypertension vs. those treated with celecoxib, according to the PRECISION-ABPM study.

Patients with atrial fibrillation who received apixaban before their scheduled cardioversion had a lower risk for stroke compared with warfarin and heparin, according to the EMANATE study presented at the European Society of Cardiology Congress.

Catheter-based renal denervation lowered BP in hypertensive patients not treated with antihypertensive medication, according to the results of the SPYRAL HTN-OFF MED trial presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.

Patients with stable atherosclerotic vascular disease who were treated with 2.5 mg of rivaroxaban plus aspirin had improved CV outcomes vs. aspirin alone, although they had more major bleeding events, according to the COMPASS study presented at the European Society of Cardiology Congress in Barcelona, Spain.

Patients with a history of MI and an elevated high-sensitivity C-reactive protein level treated with canakinumab had a lower rate of recurrent CV events compared with placebo, according to results of the CANTOS trial presented at the European Society of Cardiology Congress.

An ultra-thin sirolimus-eluting bioresorbable polymer drug-eluting stent was superior to a thin everolimus-eluting durable polymer stent for prevention of target lesion failure at 12 months, according to a late-breaking presentation from the European Society of Cardiology Congress.